Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Alexion gets positive opinion from European agency

Alexion Pharmaceuticals reports that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending marketing authorization for ULTOMIRIS®...

| By Kelley Gipson

Yale professor receives CASE science medal

The Connecticut Academy of Science and Engineering has announced that Yale School of Medicine professor Pasko Rakic is the 2019 recipient of the Connecticut Medal...

| By Kelley Gipson

Hartford partners to launch medtech accelerator

Hartford HealthCare, Trinity College and the UConn School of Business are planning the launch a medical technology and digital health accelerator, which would join insurance...

| By Kelley Gipson

BioXcel Therapeutics blooms in New Haven

Twelve stories above New Haven Harbor, BioXcel Therapeutics is using Big Data technology to mine Big Pharma chemistry and create new drugs that treat pancreatic cancer...

| By Kelley Gipson

UConn spearheads animal vaccine, ADHD research

The U.S. Department of Agriculture National Institute of Food and Agriculture has designated UConn’s CEVR (Center of Excellence for Vaccine Research) to be the National Center...

| By Kelley Gipson

Intensity gets FDA Fast Track for breast cancer drug

Intensity Therapeutics has received an FDA Fast Track designation for its INT230-6 for the treatment of patients with relapsed or metastatic triple negative breast cancer (TNBC)...

| By Kelley Gipson

CT one of top 5 states with ‘innovative economies’

Connecticut is in the top 5 states leading the nation in innovative economies, according to a Bloomberg report. “The state’s defense, aerospace, and biotechnology sectors are...

| By Kelley Gipson

Arvinas protein degrader therapeutic hits clinic

New therapeutics that harness cellular machinery to degrade targets are entering clinical trials, led by a PROTAC anticancer candidate developed by Arvinas. Whereas most small...

| By Kelley Gipson

Achillion reports enrollments in two trials

Achillion reports that it achieved threshold enrollment in the Phase 2 trials of ACH-4471 for patients with C3 glomerulopathy (C3G), a devastating disease affecting the...